Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Melodiol Global Health.
RELATED STOCKHEAD STORIES
News
In Case You Missed It: Firebrick back after review points to ‘inaccuracies in trial efficacy data’
Health & Biotech
Melodiol subsidiary HHI Australia delivers $1 million revenue in October
News
In Case You Missed It: Record monthly Canadian cannabis revenue takes top spot
News
10 at 11ish: First Au gets nod for bulk sampling at Victorian gold project
Health & Biotech
‘Current inventory moving very quickly’: Melodiol’s Canadian subsidiary continues to deliver record revenue
News
Quarterly Wrap: Pot stocks shine with record revenues for Melodiol, 75pc increase in revenue for Bioxyne
News
In Case You Missed It: Quarterlies, a lithium takeover and a 1km long pegmatite body
News
Closing Bell: ASX unconvincing ahead of big CPI read and maiden address by new RBA boss
News
In Case You Missed It: Rare earths projects lead the pack
Health & Biotech
Melodiol’s Canadian subsidiary Mernova on track for highest ever monthly revenue in October
News
In Case You Missed It: Lithium takeover, a new lithium discovery and a gold asset sale
Health & Biotech
Melodiol marks another record revenue quarter with $7.5m of unaudited sales, up 265% on the PCP
News
In Case You Missed It: M&A, asset sales and biotech profits lead the way
Health & Biotech
Melodiol jumps 20pc as subsidiary Health House International’s Aussie operations deliver quarterly profit
News
In Case You Missed It: Green and brownfields gold exploration, and online marketplace boasts solid Q1
Health & Biotech
‘Nothing short of exceptional’: Melodiol’s psychedelics subsidiary shows promising Phase II PTSD trial results
News
